Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
Clinical judgment should be used in deciding whom to treat as LVEF is a variable measure.
Entresto is administered in place of an ACE inhibitor or ARB.